Cargando…

Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback

CONTEXT: Paradoxical increases in serum cortisol in the dexamethasone suppression test (DST) have been rarely observed in Cushing disease (CD). Its pathophysiology and prevalence remain unclear. CASE DESCRIPTION: A 62-year-old woman with suspected CD showed paradoxical increases in cortisol after bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsujimoto, Yasutaka, Shichi, Hiroki, Fukuoka, Hidenori, Yamamoto, Masaaki, Sato, Itsuko, Imanishi, Takamitsu, Nakamura, Tomoaki, Inoshita, Naoko, Ishida, Atsushi, Yamada, Shozo, Takahashi, Yutaka, Chihara, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143664/ https://www.ncbi.nlm.nih.gov/pubmed/34061117 http://dx.doi.org/10.1210/jendso/bvab055

Ejemplares similares

MON-905 A Case of Cushing’s Disease with Glucocorticoid Positive-Feedback
por: Shichi, Hiroki, et al.
Publicado: (2020)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

Metyrapone for Long-Term Medical Management of Cushing's Syndrome
por: Traina, Andrea N., et al.
Publicado: (2013)

Cushing Disease Treated Successfully With Metyrapone During Pregnancy
por: Bass, Ilana Ramer, et al.
Publicado: (2021)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing’s Disease
por: Fukuoka, Hidenori, et al.
Publicado: (2020)

Long-term Treatment With Metyrapone in a Man With Ectopic Cushing Syndrome
por: Wong, Tin Wai
Publicado: (2022)

Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing’s Syndromes Treatment: Case Presentations
por: Yoshida, Kenichi, et al.
Publicado: (2018)

Adrenal Cushing’s in Pregnancy, Managed with Metyrapone to Optimize for Adrenalectomy at 27 Weeks Gestation
por: Shah, Leena, et al.
Publicado: (2021)

Adrenal Cushing Syndrome Diagnosed During Pregnancy: Successful Medical Management With Metyrapone
por: Azzola, Alescia, et al.
Publicado: (2020)

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study
por: Puglisi, Soraya, et al.
Publicado: (2018)

SUN-LB068 Ectopic Cushing Syndrome Due to a Metastatic Neuroendocrine Tumor Treated with Metyrapone
por: Tsomos, Effie, et al.
Publicado: (2019)

Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome
por: Vega-Beyhart, Arturo, et al.
Publicado: (2022)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Metyrapone: Various toxicities: case report
Publicado: (2021)

Aggressive Cushing’s Disease: Molecular Pathology and Its Therapeutic Approach
por: Yamamoto, Masaaki, et al.
Publicado: (2021)

Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing’s Syndrome: Results From a Single Center Cohort Study
por: Detomas, Mario, et al.
Publicado: (2022)

RF21 | PSAT99 Urinary adrenal steroidome modifications by Ketoconazole and Metyrapone alter the urinary free cortisol immunoassay reliability in Cushing Syndrome
por: Vega-Beyhart, Arturo, et al.
Publicado: (2022)

Ketoacidosis, Hypertriglyceridemia and Acute Pancreatitis Induced by Soft Drink Polydipsia in a Patient with Occult Central Diabetes Insipidus
por: Tsujimoto, Yasutaka, et al.
Publicado: (2021)

Maternal Metyrapone Use During Breastfeeding: Safe for the Breastfed Infant
por: Duke, Madeline E, et al.
Publicado: (2019)

Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study
por: Nieman, Lynnette K, et al.
Publicado: (2021)

Cushing’s Disease
por: Nishioka, Hiroshi, et al.
Publicado: (2019)

Evaluation of plasma ACTH in the metyrapone test is insufficient for the diagnosis of secondary adrenal insufficiency
por: Papierska, Lucyna, et al.
Publicado: (2022)

Diagnostic Usefulness of 3 Tesla MRI of the Brain for Cushing Disease in a Child
por: Ono, Erina, et al.
Publicado: (2011)

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
por: He, Xin, et al.
Publicado: (2022)

ODP355 The analysis of tumor infiltrative lymphocytes in corticotroph adenomas and its relation to hormonal status
por: Fukuoka, Hidenoi, et al.
Publicado: (2022)

The behavioral and neurochemical effects of methylprednisolone or metyrapone in a post-traumatic stress disorder rat model
por: Tanriverdi, Ayse Melek, et al.
Publicado: (2019)

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review
por: Curtò, Lorenzo, et al.
Publicado: (2010)

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

Mesh shrinkage after transabdominal preperitoneal inguinal hernia repair
por: Watanobe, Ikuo, et al.
Publicado: (2023)

Case report: Late middle-aged features of FAM111A variant, Kenny–Caffey syndrome type 2-suggestive symptoms during a long follow-up
por: Ohmachi, Yuka, et al.
Publicado: (2023)

PLA(2) activity is required for nuclear shrinkage in caspase-independent cell death
por: Shinzawa, Koei, et al.
Publicado: (2003)

Cushing’s syndrome with no clinical stigmata – a variant of glucocorticoid resistance syndrome
por: Gossain, Ved V., et al.
Publicado: (2018)

On Reverse Shrinkage Effects and Shrinkage Overshoot
por: Jordan, Pascal
Publicado: (2022)

Pathway Analysis Reveals Common Pro-Survival Mechanisms of Metyrapone and Carbenoxolone after Traumatic Brain Injury
por: Hellmich, Helen L., et al.
Publicado: (2013)

Metyrapone, an inhibitor of cytochrome oxidases, does not affect viability in a neuroblastoma cell model of bilirubin toxicity
por: Naguib Leerberg, Maria N., et al.
Publicado: (2014)

Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review
por: Iwayama, Hideyuki, et al.
Publicado: (2018)

Regulation of growth hormone secretion by (pro)renin receptor
por: Tani, Yuji, et al.
Publicado: (2015)

Pre-test metyrapone impairs memory recall in fear conditioning tasks: lack of interaction with β-adrenergic activity
por: Careaga, Mariella B. L., et al.
Publicado: (2015)

SAT300 Use of Overnight Metyrapone Test In Suspected Adrenal Insufficiency: A Retrospective Single Center-Study
por: Saini, Jasmine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9976dui5n1r3qi3jc8r2fhq9v6